Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross VEGF Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedEmpire BluecrossPolicy CC-0072

    Vascular Endothelial Growth Factor (VEGF) Inhibitors

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0072 alerts

    Get alerted when Policy CC-0072 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs medical-necessity review and applicable prior authorization for intravitreal VEGF antagonists used for retinal diseases, including age-related macular degeneration, diabetic retinal disease, retinal vein occlusion, and selected rare ocular conditions, when reviewed under the medical benefit.

    Policy Summary
    PayerEmpire Bluecross
    PolicyVascular Endothelial Growth Factor (VEGF) Inhibitors
    Policy CodePolicy CC-0072
    Change TypeNo material change
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit the diagnosis and requested drug information supporting the applicable medical-necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8VEGF inhibitor categories or agents addressed
    9Diagnosis categories for the Avastin-related agent group
    1Preferred-agent trial pathway
    2 mg q4wkStandard aflibercept quantity limit
    8 mg q4wkEylea HD quantity limit

    Coverage Criteria

    Vabysmo (faricimab-svoa)

    Covered when the individual has a diagnosis of at least one of the following:

    ONE of the following diagnoses

    • Diabetic macular edema (DME), including DME with diabetic retinopathy of any severity
    • Proliferative or moderate to severe non-proliferative diabetic retinopathy, with or without diabetic macular edema
    • Established neovascular (wet) age-related macular degeneration
    • Macular edema following retinal vein occlusion (RVO)
    • Neovascular glaucoma
    Policy Summary
    PayerEmpire Bluecross
    PolicyVascular Endothelial Growth Factor (VEGF) Inhibitors
    Policy CodePolicy CC-0072
    Change TypeNo material change
    Effective DateSep 18, 2026
    Last ReviewAug 14, 2026
    Next Review DateN/A
    Key ActionSubmit the diagnosis and requested drug information supporting the applicable medical-necessity criteria.
    SourceLink
    On This Page
    Coverage CriteriaBilling and Diagnosis CodesProvider Requirements and Review RulesClinical BackgroundClinical and Product DefinitionsInitial Therapy CriteriaStep Therapy RequirementsDose and Frequency LimitsBiosimilar and Interchangeable Products
  1. Choroidal neovascularization associated with myopic degeneration
  2. Other rare causes of choroidal neovascularization, including angioid streaks; choroiditis (including, but not limited to, histoplasmosis-induced choroiditis); retinal dystrophies; trauma; or pseudoxanthoma elasticum
  3. Radiation retinopathy
  4. Retinopathy of prematurity
  5. Avastin, Alymsys, Jobevne, Lytenava, Mvasi, Vegzelma, or Zirabev (bevacizumab agents)

    Covered when the individual has a diagnosis of at least one of the following:

    ONE of the following diagnoses

    • Diabetic macular edema (DME), including DME with diabetic retinopathy of any severity
    • Proliferative or moderate to severe non-proliferative diabetic retinopathy, with or without diabetic macular edema
    • Established neovascular (wet) age-related macular degeneration
    • Macular edema following retinal vein occlusion (RVO)
    • Neovascular glaucoma
    • Choroidal neovascularization associated with myopic degeneration
    • Other rare causes of choroidal neovascularization, including angioid streaks; choroiditis (including, but not limited to, histoplasmosis-induced choroiditis); retinal dystrophies; trauma; or pseudoxanthoma elasticum
    • Radiation retinopathy
    • Retinopathy of prematurity

    Lucentis, Byooviz, Cimerli, or Nufymco (ranibizumab agents)

    Covered when the individual has a diagnosis of at least one of the following:

    ONE of the following diagnoses

    • Diabetic macular edema (DME), including DME with diabetic retinopathy of any severity
    • Proliferative or moderate to severe non-proliferative diabetic retinopathy, with or without diabetic macular edema
    • Established neovascular (wet) age-related macular degeneration
    • Macular edema following retinal vein occlusion (RVO)
    • Choroidal neovascularization associated with myopic degeneration
    • Radiation retinopathy

    Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, or Yesafili (standard aflibercept agents)

    Covered when the individual has a diagnosis of at least one of the following:

    ONE of the following diagnoses

    • Diabetic macular edema (DME), including DME with diabetic retinopathy of any severity
    • Proliferative or moderate to severe non-proliferative diabetic retinopathy, with or without diabetic macular edema
    • Established neovascular (wet) age-related macular degeneration
    • Macular edema following retinal vein occlusion (RVO)
    • Retinopathy of prematurity

    Eylea HD (aflibercept)

    Covered when the individual has a diagnosis of at least one of the following:

    ONE of the following diagnoses

    • Neovascular (wet) age-related macular degeneration (nAMD)
    • Diabetic retinopathy (DR)
    • Diabetic macular edema (DME)
    • Macular edema following retinal vein occlusion (RVO)

    Beovu (brolucizumab-dbll)

    Covered when the individual has a diagnosis of at least one of the following:

    ONE of the following diagnoses

    • Established neovascular (wet) age-related macular degeneration
    • Diabetic macular edema (DME), including DME with diabetic retinopathy of any severity

    Coverage is not available when the applicable diagnosis criteria above are not met. The listed VEGF inhibitor agents are not approved for coverage for unlisted or other indications.

    Billing and Diagnosis Codes

    Intravitreal bevacizumab HCPCS codesHCPCS
    C9257Injection, bevacizumab, 0.25 mg [Avastin]
    C9399Unclassified drugs or biologicals [when specified as Lytenava (bevacizumab-vikg)]
    J3590Unclassified biologics [when specified as Lytenava (bevacizumab-vikg)]
    J9035Injection, bevacizumab, 10 mg [when specified as Avastin intravitreal]
    Q5126Injection, bevacizumab-maly, biosimilar, (Alymsys), 10 mg
    Q5129Injection, bevacizumab-adcd (Vegzelma), biosimilar, 10 mg
    Q5107Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
    Q5118Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg
    Q5160Injection, bevacizumab-nwgd (Jobevne), biosimilar, 10 mg
    Intravitreal bevacizumab ICD-10 diagnosis codesICD-10
    B39.0-B39.9Histoplasmosis
    E08.311-E08.3519Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3521-E08.3599Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy [without macular edema]
    E09.311-E09.3519Drug or chemical induced diabetes mellitus with diabetic retinopathy with macular edema
    E09.3521-E09.3599Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E10.311-E10.3519Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    1–10 of 37
    1/4
    Intravitreal ranibizumab procedure codeCPT
    67028Intravitreal injection of a pharmacologic agent [when billed in conjunction with intravitreal injection of ranibizumab HCPCS code listed below]
    Intravitreal ranibizumab HCPCS codesHCPCS
    J2778Injection, ranibizumab; 0.1 mg [Lucentis]
    Q5124Injection, ranibizumab-nuna, biosimilar, (Byooviz), 0.1 mg
    Q5128Injection, ranibizumab-eqrn (Cimerli), biosimilar, 0.1 mg
    Q5168Injection, ranibizumab-leyk (Nufymco), biosimilar, 0.1 mg
    Intravitreal ranibizumab ICD-10 diagnosis codesICD-10
    E08.311-E08.3519Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3521-E08.3599Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy [without macular edema]
    E09.311-E09.3519Drug or chemical induced diabetes mellitus with diabetic retinopathy with macular edema
    E09.3521-E09.3599Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E10.311-E10.3519Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    1–10 of 24
    1/3
    Intravitreal aflibercept procedure codeCPT
    67028Intravitreal injection of a pharmacologic agent [when billing in conjunction with intravitreal injection of aflibercept HCPCS code listed below]
    Intravitreal aflibercept HCPCS codesHCPCS
    J0178Injection, aflibercept, 1 mg [Eylea]
    Q5147Injection, aflibercept-ayyh (Pavblu), biosimilar, 1 mg
    Q5149Injection, aflibercept-abzv (Enzeevu), biosimilar, 1 mg
    Q5150Injection, aflibercept-mrbb (Ahzantive), biosimilar, 1 mg
    Q5153Injection, aflibercept-yszy (Opuviz), biosimilar, 1 mg
    Q5155Injection, aflibercept-jbvf (Yesafili), biosimilar, 1 mg
    Q5170Injection, aflibercept-boav (Eydenzelt), biosimilar, 1 mg
    Intravitreal aflibercept ICD-10 diagnosis codesICD-10
    E08.311-E08.3519Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3521-E08.3599Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy [without macular edema]
    E10.311-E10.3519Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    H34.8110Central retinal vein occlusion, right eye, with macular edema
    H34.8120Central retinal vein occlusion, left eye, with macular edema
    1–10 of 18
    1/2
    Eylea HD procedure codeCPT
    67028Intravitreal injection of a pharmacologic agent
    CPTCPT
    67028Intravitreal injection of a pharmacologic agent
    HCPCSHCPCS
    J0177Injection, aflibercept HD, 1 mg [Eylea HD]
    ICD-10 DiagnosisICD-10
    E08.311Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.319Diabetes mellitus due to underlying condition with diabetic retinopathy, when specified as proliferative diabetic retinopathy
    E08.3211-E08.3219Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3311-E08.3319Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3411-E08.3419Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3511-E08.3519Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
    E08.3521-E08.3599Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema
    E10.311Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.319Type 1 diabetes mellitus with diabetic retinopathy, when specified as proliferative diabetic retinopathy
    E10.3211-E10.3219Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    1–10 of 21
    1/3
    ICD-10 DiagnosisICD-10
    E10.311Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3211-E10.3219Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3311-E10.3319Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3411-E10.3419Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3511-E10.3519Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.319Type 1 diabetes mellitus with proliferative diabetic retinopathy when specified as proliferative diabetic retinopathy
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    ICD-10 DiagnosisICD-10
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema; includes only code E11.311 and ranges E11.3211-E11.3219, E11.3311-E11.3319, E11.3411-E11.3419, E11.3511-E11.3519, and E11.319 when specified as proliferative diabetic retinopathy
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    ICD-10 DiagnosisICD-10
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    ICD-10 DiagnosisICD-10
    E10.319Type 1 diabetes mellitus with diabetic retinopathy; when specified as proliferative diabetic retinopathy
    E10.3411-E10.3419Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3511-E10.3519Type 1 diabetes mellitus with diabetic retinopathy with macular edema
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with diabetic retinopathy; when specified as proliferative diabetic retinopathy
    E11.3211-E11.3219Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3311-E11.3319Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3411-E11.3419Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    1–10 of 18
    1/2
    ICD-10 DiagnosisICD-10
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3311-E11.3319Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3411-E11.3419Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with diabetic retinopathy with macular edema when specified as proliferative diabetic retinopathy
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3211-E13.3219Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3311-E13.3319Other specified diabetes mellitus with diabetic retinopathy with macular edema
    1–10 of 14
    1/2
    ICD-10 DiagnosisICD-10
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    ICD-10 DiagnosisICD-10
    E10.3521-E10.3599Type 1 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    H34.8110Central retinal vein occlusion, right eye, with macular edema
    H34.8120Central retinal vein occlusion, left eye, with macular edema
    ICD-10 DiagnosisICD-10
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with diabetic retinopathy; included when specified as proliferative diabetic retinopathy
    E11.3211-E11.3219Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3311-E11.3319Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3411-E11.3419Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.319Other specified diabetes mellitus with diabetic retinopathy; included when specified as proliferative diabetic retinopathy
    E13.3211-E13.3219Other specified diabetes mellitus with diabetic retinopathy with macular edema
    1–10 of 16
    1/2
    ICD-10 DiagnosisICD-10
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    H34.8110Central retinal vein occlusion, right eye, with macular edema
    H34.8120Central retinal vein occlusion, left eye, with macular edema
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    ICD-10 DiagnosisICD-10
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    H34.8110Central retinal vein occlusion, right eye, with macular edema
    H34.8120Central retinal vein occlusion, left eye, with macular edema
    H34.8130Central retinal vein occlusion, bilateral, with macular edema
    ICD-10 DiagnosisICD-10
    E11.311-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.311Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3211-E11.3219Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3311-E11.3319Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3411-E11.3419Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with diabetic retinopathy; included when specified as proliferative diabetic retinopathy
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.311Other specified diabetes mellitus with diabetic retinopathy with macular edema
    1–10 of 18
    1/2
    Diabetic retinopathy diagnosis codesICD-10
    E11.311Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with unspecified diabetic retinopathy, when specified as proliferative diabetic retinopathy
    E11.3211-E11.3219Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
    E11.3311-E11.3319Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
    E11.3411-E11.3419Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
    Retinal vein occlusion diagnosis codesICD-10
    H34.8110Central retinal vein occlusion, right eye, with macular edema
    H34.8120Central retinal vein occlusion, left eye, with macular edema
    H34.8130Central retinal vein occlusion, bilateral, with macular edema
    ICD-10 DiagnosisICD-10
    E11.3411-E11.3419Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with diabetic retinopathy; included when specified as proliferative diabetic retinopathy
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3521-E13.3599Other specified diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    H34.8110Central retinal vein occlusion, right eye, with macular edema
    H34.8120Central retinal vein occlusion, left eye, with macular edema
    H34.8130Central retinal vein occlusion, bilateral, with macular edema
    ICD-10 DiagnosisICD-10
    E11.3411-E11.3419Type 2 diabetes mellitus with diabetic retinopathy with macular edema
    E11.3511-E11.3519Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
    E11.319Type 2 diabetes mellitus with diabetic retinopathy, when specified as proliferative diabetic retinopathy
    E11.3521-E11.3599Type 2 diabetes mellitus with proliferative diabetic retinopathy [without macular edema]
    E13.311Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3211-E13.3219Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3311-E13.3319Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3411-E13.3419Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.3511-E13.3519Other specified diabetes mellitus with diabetic retinopathy with macular edema
    E13.319Other specified diabetes mellitus with diabetic retinopathy, when specified as proliferative diabetic retinopathy
    1–10 of 15
    1/2

    Provider Requirements and Review Rules

    Documentation Required

    Medical Necessity Review Required

    When a VEGF inhibitor is reviewed under the member’s medical benefit or is otherwise subject to clinical review, including prior authorization, apply the policy’s medical-necessity criteria for the intended or prescribed use. Submit documentation showing the requested agent and the applicable diagnosis.

    • Vabysmo (faricimab-svoa): established neovascular (wet) age-related macular degeneration; diabetic macular edema, including DME with diabetic retinopathy of any severity; macular edema following retinal vein occlusion; proliferative or moderate-to-severe non-proliferative diabetic retinopathy with or without DME; neovascular glaucoma; choroidal neovascularization associated with myopic degeneration; rare causes of choroidal neovascularization associated with angioid streaks, choroiditis, retinal dystrophies, trauma, or pseudoxanthoma elasticum; radiation retinopathy; or retinopathy of prematurity.
    • Avastin and listed bevacizumab agents: the diagnoses listed for Vabysmo above, including the additional ophthalmic indications of neovascular glaucoma, myopic choroidal neovascularization, rare causes of choroidal neovascularization, radiation retinopathy, and retinopathy of prematurity.
    • Lucentis, Byooviz, Cimerli, and Nufymco: diabetic macular edema; proliferative or moderate-to-severe non-proliferative diabetic retinopathy with or without DME; established neovascular (wet) age-related macular degeneration; macular edema following RVO; choroidal neovascularization associated with myopic degeneration; or radiation retinopathy.
    • Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, and Yesafili: diabetic macular edema; proliferative or moderate-to-severe non-proliferative diabetic retinopathy with or without DME; established neovascular (wet) age-related macular degeneration; macular edema following RVO; or retinopathy of prematurity.
    • Eylea HD (aflibercept): neovascular (wet) age-related macular degeneration, diabetic retinopathy, diabetic macular edema, or macular edema following RVO.
    • Beovu (brolucizumab-dbll): established neovascular (wet) age-related macular degeneration or diabetic macular edema, including DME with diabetic retinopathy of any severity.
    Prior Authorization

    Bevacizumab-Agent Precertification

    Precertification may not be required for intravitreal Avastin or the listed bevacizumab products. Verify the member-specific benefit and precertification requirements before treatment, and use the medical-necessity criteria when clinical review applies.

    • Avastin (bevacizumab)
    • Alymsys (bevacizumab-maly)
    • Jobevne (bevacizumab-nwgd)
    • Lytenava (bevacizumab-vikg)
    • Mvasi (bevacizumab-awwb)
    • Vegzelma (bevacizumab-adcd)
    • Zirabev (bevacizumab-bvzr)
    • For additional precertification information, use the policy’s linked resource.
    Step Therapy

    Preferred-Agent Sequencing

    When an intravitreal VEGF antagonist is clinically approvable, the member’s benefit plan may require sequencing through a preferred intravitreal VEGF antagonist. Check the plan’s current preferred-agent list and obtain an exception for a non-preferred agent when one of the policy pathways applies.

    • Preferred agents are those considered clinically comparable within the same class or disease category and preferred based on clinical evidence and cost effectiveness.
    • The preferred intravitreal VEGF antagonist list is available through the policy’s linked resource.
    • A non-preferred agent may be considered when the individual is already receiving it; has tried and had an inadequate response or intolerance to a preferred agent; or the preferred agents lack FDA approval and an accepted off-label use for the prescribed indication while the requested agent has one.
    • A non-preferred agent may be approved for a diagnosis other than age-related macular degeneration when Avastin is the sole preferred agent approvable for that diagnosis.
    • Lucentis, Byooviz, Cimerli, or Nufymco may be approved for supplemental injections when the individual has a Susvimo ocular implant.
    • Eylea, Enzeevu, Pavblu, Ahzantive, Yesafili, Opuviz, or Eydenzelt may be approved for retinopathy of prematurity.
    Denial Risk

    Unlisted Indication May Be Denied

    Requests may not be approved when the applicable agent-specific diagnosis criteria are not met or for indications outside those criteria. This denial risk applies to Vabysmo, the listed bevacizumab agents, Lucentis/Byooviz/Cimerli/Nufymco, the listed aflibercept agents including Eylea HD, and Beovu.

    • Confirm that the diagnosis matches an indication specifically listed for the requested product.
    • For intravitreal Avastin and the listed bevacizumab agents, requests may not be approved when the applicable criteria are not met or for all other indications.
    • For Lucentis, Byooviz, Cimerli, Nufymco, Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, Yesafili, Eylea HD, and Beovu, requests may not be approved when the applicable criteria are not met or for all other indications.
    • Do not assume that coverage for one VEGF inhibitor establishes coverage for another; apply the requested agent’s diagnosis-specific criteria.
    Step Therapy

    Non-Preferred Agent Exception Required

    For a non-preferred intravitreal VEGF antagonist, document the applicable exception pathway before requesting approval. Clinical approval under the diagnosis criteria does not by itself waive the preferred-agent requirement.

    • Document that the individual has been receiving the requested agent; or
    • Document a trial of, and inadequate response or intolerance to, one preferred agent.
    • If relevant, document that preferred agents are not FDA-approved and have no accepted off-label use under the off-label use policy for the prescribed indication, while the requested non-preferred agent does.
    • For a diagnosis other than age-related macular degeneration, document when Avastin is the sole preferred agent approvable for that diagnosis.
    • For supplemental injections, document the presence of a Susvimo ocular implant when requesting Lucentis, Byooviz, Cimerli, or Nufymco.
    • For retinopathy of prematurity, document the diagnosis when requesting Eylea, Enzeevu, Pavblu, Ahzantive, Yesafili, Opuviz, or Eydenzelt.
    Denial Risk

    Quantity Limits and Treatment Intervals

    Administer VEGF antagonists within the policy’s quantity and frequency limits. Requests that exceed the listed dose, number of units, per-eye limit, or treatment interval may be denied or require review.

    • For Eylea (aflibercept) 2 mg and the listed 2 mg aflibercept products Enzeevu, Pavblu, Yesafili, Ahzantive, and Opuviz: quantity limit 1; for diabetic macular edema, diabetic retinopathy, neovascular (wet) age-related macular degeneration, and retinal vein occlusion, 2 mg per eye, with each eye treated no more frequently than every 4 weeks.
    • For retinopathy of prematurity, the listed aflibercept limit is 0.4 mg per eye; the source table specifies treatment as frequently as every 10 days for Opuviz and Eydenzelt.
    • For Opuviz and Eydenzelt, the source table lists 8 mg per eye every 4 weeks (approximately every 28 days, plus or minus 7 days) for diabetic macular edema, diabetic retinopathy, neovascular (wet) age-related macular degeneration, and macular edema following retinal vein occlusion.
    • For Eylea HD (aflibercept) 8 mg: quantity limit 1 and 8 mg per eye every 4 weeks, approximately every 28 days plus or minus 7 days.
    • For ranibizumab products, the source table lists 0.3 mg per eye every 4 weeks for diabetic macular edema and diabetic retinopathy, and 0.5 mg per eye every 4 weeks for age-related macular degeneration, branch or central retinal vein occlusion, myopic choroidal neovascularization, and radiation retinopathy; Byooviz is listed as a 0.5 mg vial with a 4-week interval.

    Clinical Background

    Intravitreal VEGF antagonists are used to treat retinal disorders involving abnormal vascular growth or vascular leakage. Clinical applications include neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion. The policy also addresses selected ocular conditions, including neovascular glaucoma, choroidal neovascularization, radiation retinopathy, and retinopathy of prematurity. Intravitreal injections carry risks such as infection, retinal detachment, traumatic lens injury, and increased intraocular pressure; aseptic technique, patient education, and post-injection monitoring are important.

    Clinical and Product Definitions

    Neovascular (wet) age-related macular degeneration
    ConditionAge-related macular degeneration involving abnormal blood vessels behind the retina.
    Also calledWet or neovascular age-related macular degeneration.
    Clinical effectFragile abnormal vessels can cause rapid loss of central vision over weeks to months.
    Retinal vein occlusion
    DefinitionA blockage of the blood supply from the retina.
    Associated conditionsIt may be caused by a blood clot, diabetes, glaucoma, atherosclerosis, or hypertension.
    Possible complicationMacular edema may complicate central or branch retinal vein occlusions.
    Diabetic retinopathy and diabetic macular edema
    CauseChronically high blood sugar disrupts blood flow and damages the retina’s tiny blood vessels.
    Diabetic retinopathyAdvanced disease can cause abnormal blood vessels to grow on the retinal surface; this severe form is called proliferative diabetic retinopathy.
    Diabetic macular edemaFluid leaking into the center of the macula causes swelling and blurred vision; macular edema can occur at any stage of diabetic retinopathy.
    Biosimilar
    DefinitionA biological product highly similar to a reference product with no clinically meaningful differences in safety, purity, or potency.
    Required similarityThe biosimilar uses the same mechanism of action, route of administration, dosage form, and strength as the reference product.
    IndicationsIndications proposed for the biosimilar must have been previously approved for the reference product; approval may rely on scientifically justified extrapolation of data.
    Interchangeable product
    Approval basisA product approved based on evidence that it is highly similar to an FDA-approved reference product.
    Clinical differencesThere are no clinically meaningful differences between the interchangeable product and the reference product.
    Switching expectationThe products are expected to produce the same clinical result, and alternating between them does not create greater safety or diminished-efficacy risk than continued reference-product use.

    Initial Therapy Criteria

    Vabysmo Initial Therapy Criteria

    Vabysmo may be approved when the diagnosis criterion is met:

    Diagnosis: Established neovascular wet age-related macular degeneration; diabetic macular edema, including DME with diabetic retinopathy of any severity; or macular edema following retinal vein occlusion

    Bevacizumab Agents Initial Therapy Criteria

    The listed bevacizumab agents may be approved when one qualifying diagnosis is present:

    Diagnosis: Diabetic macular edema; proliferative or moderate to severe non-proliferative diabetic retinopathy with or without diabetic macular edema; established neovascular wet age-related macular degeneration; macular edema following retinal vein occlusion; neovascular glaucoma; choroidal neovascularization associated with myopic degeneration; specified rare causes of choroidal neovascularization; radiation retinopathy; or retinopathy of prematurity

    Other VEGF Inhibitors Initial Therapy Criteria

    Each requested agent may be approved when one of its specified diagnoses is present:

    Agent-specific diagnosis: For ranibizumab agents—Lucentis, Byooviz, Cimerli, or Nufymco—the individual has diabetic macular edema, qualifying diabetic retinopathy, neovascular wet age-related macular degeneration, macular edema following retinal vein occlusion, choroidal neovascularization associated with myopic degeneration, or radiation retinopathy; for standard aflibercept agents—Eylea, Ahzantive, Enzeevu, Eydenzelt, Opuviz, Pavblu, or Yesafili—the individual has diabetic macular edema, qualifying diabetic retinopathy, neovascular wet age-related macular degeneration, macular edema following retinal vein occlusion, or retinopathy of prematurity; for Eylea HD, the individual has neovascular wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, or macular edema following retinal vein occlusion; or for Beovu, the individual has established neovascular wet age-related macular degeneration or diabetic macular edema, including DME with diabetic retinopathy of any severity

    Step Therapy Requirements

    StepRequirementExceptions for approval
    1Use a preferred intravitreal VEGF antagonist before a non-preferred agent.A non-preferred agent may be approved if the individual is already receiving the requested agent; has tried and had an inadequate response or intolerance to one preferred agent; the preferred agents lack an FDA-approved or accepted off-label use for the indication while the requested agent has one; or Avastin is the sole preferred agent approvable for a diagnosis other than age-related macular degeneration.
    StepAgentsApproval conditionCoverage
    2Lucentis, Byooviz, Cimerli, or NufymcoThe individual currently has a Susvimo ocular implant and is requesting supplemental injections.May be approved
    StepAgentsApproval conditionCoverage
    3Eylea, Enzeevu, Pavblu, Ahzantive, Yesafili, Opuviz, or EydenzeltThe individual has a diagnosis of retinopathy of prematurity.May be approved

    Dose and Frequency Limits

    Quantity limits
    Dose2 mg per eye for diabetic macular edema, diabetic retinopathy, neovascular wet age-related macular degeneration, or retinal vein occlusion; 0.4 mg per eye for retinopathy of prematurity.
    Treatment intervalFor diabetic macular edema, diabetic retinopathy, neovascular wet age-related macular degeneration, or retinal vein occlusion, each eye may be treated as frequently as every 4 weeks.
    ProductsEylea, Enzeevu, Pavblu, Yesafili, Ahzantive, and Opuviz.
    Quantity limits
    Retinopathy of prematurity0.4 mg per eye; each eye may be treated as frequently as every 10 days.
    Other retinal indications8 mg per eye every 4 weeks, approximately every 28 days plus or minus 7 days, for diabetic macular edema, diabetic retinopathy, neovascular wet age-related macular degeneration, or macular edema following retinal vein occlusion.
    ProductEydenzelt.
    Quantity limits
    Dose8 mg per eye.
    Treatment intervalEvery 4 weeks, approximately every 28 days plus or minus 7 days.
    ProductEylea HD.
    Quantity limits
    Diabetic macular edema and diabetic retinopathy0.3 mg per eye; each eye may be treated as frequently as every 4 weeks.
    Age-related macular degeneration, retinal vein occlusion, myopic choroidal neovascularization, and radiation retinopathy0.5 mg per eye; each eye may be treated as frequently as every 4 weeks.
    ProductsLucentis, Byooviz, Cimerli, and Nufymco.
    Quantity limits
    Standard retinal indications2 mg per eye for diabetic macular edema, diabetic retinopathy, wet age-related macular degeneration, and retinal vein occlusion.
    Treatment intervalEach eye may be treated as frequently as every 4 weeks.
    Retinopathy of prematurity0.4 mg per eye.
    Quantity limits
    Dose0.4 mg per eye.
    Treatment intervalEach eye may be treated as frequently as every 10 days.
    Product and indicationEydenzelt for retinopathy of prematurity.
    Quantity limits
    Dose8 mg per eye.
    Treatment intervalEvery 4 weeks, approximately every 28 days plus or minus 7 days.
    ProductEylea HD.
    Quantity limits across indications
    Diabetic macular edema and diabetic retinopathy0.3 mg per eye; each eye may be treated as frequently as every 4 weeks.
    Age-related macular degeneration, branch or central retinal vein occlusion, myopic choroidal neovascularization, and radiation retinopathy0.5 mg per eye; each eye may be treated as frequently as every 4 weeks.
    ProductsLucentis, Byooviz, Cimerli, and Nufymco.
    Quantity limits
    Dose1.25 mg per eye.
    Treatment intervalEach eye may be treated as frequently as every 4 weeks when used for ophthalmologic indications.
    ProductsAvastin, Lytenava, Mvasi, Vegzelma, and Zirabev.
    Quantity limits
    Dose6 mg per eye.
    Treatment intervalEach eye may be treated as frequently as every 8 weeks.
    ProductBeovu.
    Quantity limits
    Dose6 mg per eye.
    Treatment intervalEach eye may be treated as frequently as every 4 weeks.
    IndicationsDiabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion.

    Biosimilar and Interchangeable Products

    Billing Rule

    Apply Avastin biosimilar use considerations

    Alymsys, Mvasi, Zirabev, and Vegzelma are FDA-approved biosimilars to Avastin and share Avastin’s FDA-approved uses except hepatocellular carcinoma. Although these products have not been studied in ophthalmic indications, the policy states that biosimilarity may be extrapolated to other FDA-approved and off-label indications.

    • Alymsys (bevacizumab-maly)
    • Mvasi (bevacizumab-awwb)
    • Zirabev (bevacizumab-bvzr)
    • Vegzelma (bevacizumab-adcd)
    Billing Rule

    Identify Eylea biosimilar products

    Enzeevu, Pavblu, Ahzantive, Yesafili, Opuviz, and Eydenzelt are FDA-approved biosimilars for Eylea (aflibercept). Confirm the selected product and its applicable indication when preparing the request.

    • Enzeevu (aflibercept-abzv)
    • Pavblu (aflibercept-ayyh)
    • Ahzantive (aflibercept-mrbb)
    • Yesafili (aflibercept-jbvf)
    • Opuviz (aflibercept-yszy)
    • Eydenzelt (aflibercept-boav)
    Billing Rule

    Use Byooviz for applicable Lucentis indications

    Byooviz is an FDA-approved biosimilar to Lucentis with indications for age-related macular degeneration, retinal vein occlusion, and myopic choroidal neovascularization. Although it is not FDA-approved for diabetic macular edema or diabetic retinopathy, the policy states that efficacy may be extrapolated based on biosimilarity.

    Billing Rule

    Recognize Lucentis interchangeable products

    Cimerli and Nufymco are designated interchangeable products to Lucentis. When selecting or documenting one of these products, identify its interchangeable status relative to the Lucentis reference product.

    • Cimerli (ranibizumab-eqrn)
    • Nufymco (ranibizumab-leyk)